Summary & Overview
CPT 95911: Nerve Conduction Studies, 9–10 Studies
CPT code 95911 represents nerve conduction studies involving 9–10 individual tests, a critical diagnostic tool in neurology and neuromuscular medicine. This procedure is widely used to evaluate peripheral nerve function and is essential for diagnosing conditions such as carpal tunnel syndrome and other neuropathies. The code is recognized by major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, ensuring broad coverage for patients across the United States.
This publication provides a comprehensive overview of 95911, including its clinical context, typical sites of service, and its role in the broader landscape of neurology and physical medicine. Readers will gain insight into payer coverage, relevant policy updates, and benchmarks related to the use of this code. The analysis also highlights associated modifiers and taxonomies, offering clarity on billing practices and compliance requirements. By understanding the nuances of 95911, stakeholders can better navigate the complexities of medical billing and reimbursement for nerve conduction studies.
CPT Code Overview
CPT code 95911 is used to report nerve conduction studies involving 9–10 individual studies. This procedure is a key component in the evaluation of neuromuscular disorders and is commonly performed within the field of neurology and neuromuscular medicine. Typical sites of service include outpatient clinics or office settings, such as Place of Service 11. The nerve conduction study helps clinicians assess the function of peripheral nerves, aiding in the diagnosis and management of conditions like carpal tunnel syndrome and other neuropathies.
Clinical & Coding Specifications
Clinical Context
A patient presents to a neurology or physical medicine and rehabilitation clinic with symptoms suggestive of nerve dysfunction, such as numbness, tingling, or weakness in the upper limbs. The clinician suspects carpal tunnel syndrome based on history and physical examination. To confirm the diagnosis and assess the severity, the provider orders nerve conduction studies. During the outpatient visit, 9–10 individual nerve conduction studies are performed, targeting relevant nerves in the affected limb(s). The procedure is typically conducted in an office or outpatient setting (e.g., Place of Service 11). Results are interpreted by a neurologist or physiatrist to guide further management.
Coding Specifications
-
Modifiers:
TC: Technical component. Used when only the technical aspect of the procedure (e.g., equipment use, technician performance) is billed.26: Professional component. Used when only the professional aspect (e.g., interpretation and report by the physician) is billed.
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
2084N0400X | Neurology |
208200000X | Physical Medicine & Rehabilitation |
These taxonomies represent providers specializing in neurology and physical medicine & rehabilitation, who are qualified to perform and interpret nerve conduction studies.
Related Diagnoses
-
G56.01: Carpal tunnel syndrome, right upper limb- This diagnosis is relevant when nerve conduction studies are performed to evaluate symptoms in the right upper limb, such as numbness or weakness, commonly associated with carpal tunnel syndrome.
-
G56.02: Carpal tunnel syndrome, left upper limb- This diagnosis is relevant when nerve conduction studies are performed to assess symptoms in the left upper limb, helping to confirm or rule out carpal tunnel syndrome.
Both codes are directly related to the clinical indication for performing nerve conduction studies, as they help diagnose and characterize carpal tunnel syndrome in the specified limb.
Related CPT Codes
-
95910: Nerve conduction studies; 7–8 studies- Used when fewer nerve conduction studies are performed. May be selected if the clinical scenario requires only 7–8 studies.
-
95912: Nerve conduction studies; 11–12 studies- Used when more extensive testing is needed, involving 11–12 studies. May be selected if the clinical scenario requires a broader assessment.
These codes are alternatives to 95911 and are chosen based on the number of nerve conduction studies performed. Only one code is reported per session, depending on the total studies completed. They are not used together in the same encounter.
National Reimbursement Benchmarks
National mean rates for CPT code 95911 show a significant gap between Medicare and commercial payers. Medicare's mean rate is $152.24, while the BUCA (average commercial) mean rate stands at $208.22, highlighting a difference of $55.98 per claim.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies across payers. Blue Cross Blue Shield exhibits the widest spread at $90.13, while Aetna has the tightest range at $73.46. This suggests that BCBS rates are more variable nationally, whereas Aetna's rates are more consistent.
The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.
State Benchmarks
State: AK1 / 50
Alaska Benchmarks
Alaska exhibits a substantial rate spread for CPT code 95911, particularly among commercial payers. For example, Blue Cross Blue Shield's 75th percentile rate is $510.06, while its 25th percentile is $333.00, resulting in a spread of $177.06. UnitedHealth Group also shows a notable spread, with a 75th percentile of $404.67 and a 25th percentile of $360.67. Medicare's spread is $116.50, from $93.00 to $209.50. This wide variation highlights significant differences in reimbursement depending on payer and provider contract.
Compared to national averages, Alaska's commercial payers consistently reimburse at much higher rates for CPT code 95911. The mean rates for Aetna, Blue Cross Blue Shield, Cigna, UnitedHealth Group, and BUCA in Alaska all exceed their respective national benchmarks by a considerable margin. The table and chart below present the full breakdown of payer-specific rates in Alaska.
Key Insights for Alaska
- Blue Cross Blue Shield and UnitedHealth Group have the highest mean rates for CPT 95911 in Alaska, both above $400.
- Medicare is the lowest paying payer in Alaska, with a mean rate of $147.64.
- All commercial payers in Alaska reimburse significantly above their respective national averages for CPT 95911.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.